Digitalization in siRNA & Oligo Therapeutics Workflows: Opportunities and Gaps Small interfering RNA (siRNA) and oligonucleotide (oligo) therapeutics are redefining precision medicine by offering unprecedented…Vinayak ManeAugust 25, 2025 Read More
Improving Target Selection & Validation – Role of QSP Target selection and validation involves identifying and validating a biological target that is involved in…Prashant SharmaDecember 18, 2023 Read More
Exploring New Frontiers: Clinical Pharmacology in Modern Drug Development In the drug development workflow, extending across the years from traditional to the precision of…Prashant SharmaDecember 1, 2023 Read More
Types of Drug Discovery Databases GOSTAR® is an integrated platform of various standalone databases with cross-indexing of chemical compounds of…Prashant SharmaSeptember 29, 2023 Read More
Significance of quantitative tools and techniques in reducing drug attrition Drug development is a complex and expensive process that involves multiple stages, including drug discovery,…Prashant SharmaJune 22, 2023 Read More
A day in the life of a clinical pharmacology expert Clinical pharmacologists understand that drug development is a complex and time-consuming activity. Let’s explore how…Prashant SharmaMarch 9, 2023 Read More
The role of key opinion leaders in accelerating COVID-19 vaccine use In this blog, we discuss the development of COVID-19 vaccines and the role of KOLs…Prashant SharmaFebruary 8, 2023 Read More
Bringing data to life with KOLs Who are KOLs? KOLs are key opinion leaders. They are experts in their scientific or…Prashant SharmaApril 16, 2022 Read More
The impact of key opinion leaders (KOLs) on the delivery of emerging novel treatments to lung cancer patients Lung cancer is one of the most common causes of death worldwide, accounting for 1.8m…Prashant SharmaApril 16, 2022 Read More
Repurposed drugs for COVID-19 Drug repurposing or repositioning is a promising approach for identifying new indications for approved or…Prashant SharmaApril 16, 2022 Read More